-
Street Abandons Genocea On Strategic Shift, CEO Says Oncology Focus Wasn't Sudden
Tuesday, September 26, 2017 - 9:01am | 318Read More...Genocea Biosciences Inc (NASDAQ: GNCA) announced a 40-percent workforce reduction Monday as it officially shifts focus to immuno-oncology and neoantigen cancer vaccines and explores strategic alternatives for its former lead candidate. The Street reacted with a sharp pullback and a Tuesday ratings...
-
Genocea Biosciences Spikes 30% After Positive Data From Phase 2 Trial
Thursday, March 31, 2016 - 10:11am | 217Read More...Shares of Genocea Biosciences Inc (NASDAQ: GNCA), a biopharmaceutical company that focuses on diseases with unmet needs, surged higher by more than 30 percent on Thursday. Genocea Biosciences announced earlier in the morning data from a 12-month Phase 2 study evaluating its lead candidate GEN...
